Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 11,031,000, a decrease of 48.4% compared to RMB 21,387,000 in 2024[3] - Net loss before tax for the year was RMB 150,355,000, representing a 10.6% improvement from a loss of RMB 168,235,000 in 2024[3] - Financing costs increased significantly by 759.4% to RMB 6,583,000 from RMB 766,000 in 2024[3] - The company reported a net loss attributable to shareholders of RMB 150,355,000 for the year ended December 31, 2025, compared to a net loss of RMB 168,235,000 in 2024, representing a 10.6% improvement[22] - The company’s other income decreased by approximately 48.4% from RMB 21.4 million in 2024 to RMB 11.0 million in 2025, primarily due to reduced government subsidies and bank interest income[60] - The net other income and losses decreased from a gain of approximately RMB 11.8 million in 2024 to a loss of approximately RMB 4.2 million in 2025, mainly due to reduced fair value gains on financial assets and increased impairment losses[62] Research and Development - The company submitted the Biologics License Application (BLA) for its core product LZ901 to the National Medical Products Administration in January 2025, which was accepted in February 2025[4] - LZ901 demonstrated superior cellular immunogenicity and safety compared to the HZ/su vaccine in a head-to-head comparative study conducted in adults aged 50 and above[4] - The company completed Phase I clinical trials for LZ901 in the United States in September 2025, showing good safety and immunogenicity results[4] - The company’s recombinant RSV vaccine has entered the pre-IND application stage as of Q4 2025[5] - The product pipeline includes three clinical-stage candidates, including the core product LZ901, and six preclinical-stage candidates as of December 31, 2025[45] - The innovative Fabite® platform enhances the development of bispecific antibodies, providing a competitive edge in treating relapsed/refractory hematological malignancies[46] - The next-generation vaccine development focuses on improving immunogenicity and safety while enhancing patient experience through innovative antigen delivery techniques[46] - The company holds seven R&D patents related to its core product across multiple countries, indicating a strong intellectual property position in key markets[45] Assets and Liabilities - Total assets as of December 31, 2025, were RMB 921,126,000, a decrease from RMB 951,606,000 in 2024[7] - The company’s net asset value decreased to RMB 660,119,000 from RMB 853,591,000 in the previous year[7] - The company’s non-current assets (excluding financial instruments) as of December 31, 2025, amounted to RMB 599,696,000, an increase from RMB 577,236,000 as of December 31, 2024[13] - The total receivables, prepayments, and other receivables as of December 31, 2025, is RMB 17,989,000, down from RMB 25,627,000 as of December 31, 2024, showing a decrease of approximately 29.8%[28] - Bank borrowings increased significantly to RMB 259,614,000 in 2025 from RMB 54,914,000 in 2024, representing an increase of approximately 371.5%[38] - The company has a new bank loan agreement for RMB 200,000,000 for the construction of a research and commercial production base in Beijing, maturing five years from the first drawdown[38] Employee and Operational Expenses - The company’s employee benefit expenses totaled RMB 40,841,000 for the year ended December 31, 2025, down from RMB 68,181,000 in 2024, indicating cost control measures[20] - The group's administrative expenses decreased by approximately 20.1% from RMB 648 million in 2024 to about RMB 518 million in 2025[64] - Research and development expenses fell by approximately 28.6% from RMB 1,351 million in 2024 to about RMB 965 million in 2025, primarily due to reduced clinical expenses for LZ901[65] - Other expenses rose by approximately 108.6% from RMB 7 million in 2024 to about RMB 16 million in 2025, mainly due to increased costs of immune testing kits[67] Shareholder and Corporate Governance - The company did not declare or pay any dividends for the year ended December 31, 2025, consistent with the previous year[21] - The board does not recommend the payment of a final dividend for the year ending December 31, 2025[101] - The company has committed to high standards of corporate governance to protect shareholder interests and has complied with all applicable governance codes[93] - The company plans to utilize the repurchased H-shares for the 2025 share incentive plan[98] Future Plans and Developments - The company plans to accelerate the clinical development of its core product LZ901 and other preclinical products, including recombinant vaccines and bispecific antibodies[58] - The company aims to expand its product pipeline through independent development and collaborations[58] - The company has set aside HKD 38.8 million for the construction of a commercial production facility in Zhuhai, expected to be completed by the end of 2026[84] - The company plans to fully utilize the net proceeds from the global offering by the end of 2027[86]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Beijing Luzhu Biotechnology Co., Ltd. 北京綠竹生物技術股份有限公司 北京綠竹生物技術股份有限公司（「本公司」，連同其附屬公司統稱為「本集團」） 董事（「董事」）會（「董事會」）宣佈，袁頴欣女士（「袁女士」）已辭任本公司的聯席 公司秘書（「聯席公司秘書」）及根據香港聯合交易所有限公司（「聯交所」）證券上 市規則（「上市規則」）第3.05條之本公司的授權代表（「授權代表」）、香港法例第 622章《公司條例》第16部所規定本公司於香港的授權代表及上市規則第19A.13(2) 條所規定於香港接收法律程序文件及通知書的授權人士（「法律程序代理人」），自 2026年3月18日起生效。 袁女士已確認與董事會並無任何意見分歧，亦無任何有關彼辭任而需要提請聯交 所及╱或本公司股東注意的事項。 委任聯席公司秘書、授權代表及法律程序代理人 於袁女士辭任後，董事會進一步欣然宣佈賴浩恩女士（ ...

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Beijing Luzhu Biotechnology Co., Ltd. 北京綠竹生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2480） 董事會會議日期 北京綠竹生物技術股份有限公司（「本公司」及其附屬公司「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，本公司將於二零二六年三月十八日（星期三）舉行 董事會會議，以（其中包括）考慮及批准本集團截至二零二五年十二月三十一日止 年度的全年業績以及考慮派發末期股息（如有）之建議。 孔健先生 香港，二零二六年三月四日 於本公告日期，董事會包括執行董事孔健先生、彭玲女士及張琰平女士；非執行 董事馬驫先生及孔雙泉先生；以及獨立非執行董事侯愛軍女士、梁偉業先生及梁 冶矢先生。 承董事會命 北京綠竹生物技術股份有限公司 主席兼執行董事 ...

公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | 本月底法定/註冊股本總額： RMB 202,449,032 備註： ...

Core Viewpoint - The company, Green Bamboo Bio-B (02480.HK), focuses on the research and development of vaccines and therapeutic biological agents, with its core product being the recombinant herpes zoster candidate vaccine LZ901, which is not yet commercialized and relies on government subsidies for revenue [1] Recent Events - The Biologics License Application (BLA) for LZ901 was accepted by the National Medical Products Administration in February 2025 and is currently under normal review, making the review results and subsequent commercialization process a focal point for the market [2] Project Progress - The company has increased its pipeline of preclinical products to six, including recombinant HSV-1 vaccine (for oral herpes) and recombinant HSV-2 vaccine (for genital herpes), with potential disclosures regarding clinical trial applications or progress in the future [3] Financial Performance - The company regularly publishes monthly reports on share changes, with the latest report for the period ending December 31, 2024, to be disclosed on January 7, 2026, which may reflect changes in shareholder structure. Financial data for 2024 shows R&D expenses of 135 million yuan and a pre-tax loss of 168 million yuan, narrowing by 32.5% year-on-year. Investors should pay attention to the full-year performance announcement for 2025 to assess operational improvements [4] Company Status - The latest ESG rating from Huazheng Index as of October 31, 2025, is BB, ranking 25th in the industry. Any adjustments to this rating may impact the attention of institutional investors [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | 本月底法定/註冊股本總額： RMB 202,449,032 因本公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | 本月底法定/註冊股本總額： RMB 202,449,032 備註： ...

致：香港交易及結算所有限公司 公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | 本月底法定/註冊股本總額： RMB 202,449,032 備註 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2025年11月3日 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RM ...

Core Viewpoint - The Phase I clinical trial of LZ901 vaccine conducted in the United States has been successfully completed, demonstrating good safety and immunogenicity in both high-dose and low-dose groups compared to the placebo group, laying the foundation for subsequent clinical research [1] Group 1: Clinical Trial Results - The Phase I clinical trial primarily aimed to verify the safety of the vaccine, with only the low-dose group showing mild adverse reactions related to the vaccine at a rate of 4.35%, while no adverse reactions were reported in the high-dose and placebo groups [1] - Both high-dose and low-dose groups of the LZ901 vaccine exhibited good safety and immunogenicity compared to the placebo group [1] Group 2: Product Development - LZ901 is a self-developed recombinant shingles vaccine by the company, targeting the prevention of shingles and related complications in adults aged 40 and above [1] - The Phase III clinical trial of LZ901 in China has met its clinical preset goals and achieved expected clinical results [1] - As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of China and is currently under evaluation [1]